| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/16/2023 | -9.48% | Goldman Sachs | $28 → $32 | Maintains | Sell |
| 08/07/2023 | 18.81% | Barrington Research | → $42 | Reiterates | Outperform → Outperform |
| 05/25/2023 | 18.81% | Barrington Research | → $42 | Reiterates | → Outperform |
| 05/10/2023 | 18.81% | Barrington Research | $48 → $42 | Maintains | Outperform |
| 02/08/2023 | -20.79% | Goldman Sachs | $25 → $28 | Maintains | Sell |
| 02/08/2023 | 35.79% | Barrington Research | → $48 | Reiterates | → Outperform |
| 11/03/2022 | -29.28% | Goldman Sachs | $22.6 → $25 | Maintains | Sell |
| 08/10/2022 | 35.79% | Barrington Research | $40 → $48 | Maintains | Outperform |
| 08/10/2022 | -36.07% | Goldman Sachs | $20 → $22.6 | Maintains | Sell |
| 08/26/2021 | -20.79% | BMO Capital | $26 → $28 | Maintains | Market Perform |
| 08/25/2021 | -49.08% | Goldman Sachs | $16 → $18 | Maintains | Sell |
| 05/25/2021 | -26.45% | Morgan Stanley | $19 → $26 | Maintains | Equal-Weight |
| 03/10/2021 | -46.25% | Morgan Stanley | $18 → $19 | Maintains | Equal-Weight |
| 02/25/2021 | -49.08% | Morgan Stanley | $17 → $18 | Maintains | Equal-Weight |
| 08/03/2020 | -51.91% | Morgan Stanley | $16 → $17 | Maintains | Equal-Weight |
| 07/15/2020 | -43.42% | Northcoast Research | → $20 | Upgrades | Neutral → Buy |
| 06/17/2020 | -54.74% | Morgan Stanley | $15 → $16 | Maintains | Equal-Weight |
| 04/07/2020 | -57.57% | Morgan Stanley | $24 → $15 | Maintains | Equal-Weight |
| 03/31/2020 | -49.08% | Barrington Research | $25 → $18 | Maintains | Outperform |
| 03/06/2020 | -32.11% | Morgan Stanley | $25 → $24 | Maintains | Equal-Weight |
| 03/06/2020 | -49.08% | BTIG | $19 → $18 | Maintains | Sell |
| 12/06/2019 | -23.62% | Morgan Stanley | $28 → $27 | Maintains | Equal-Weight |
| 11/22/2019 | -20.79% | Jefferies | → $28 | Initiates Coverage On | → Hold |
| 08/29/2019 | -20.79% | Morgan Stanley | $29 → $28 | Maintains | Equal-Weight |
| 07/09/2019 | — | Northcoast Research | Downgrades | Buy → Neutral | |
| 06/27/2019 | -17.96% | Morgan Stanley | → $29 | Assumes | → Equal-Weight |
| 01/31/2019 | -37.77% | Goldman Sachs | → $22 | Downgrades | Neutral → Sell |
| 12/07/2018 | -23.62% | Morgan Stanley | $26 → $27 | Maintains | Equal-Weight |
| 08/29/2018 | -26.45% | Morgan Stanley | $27 → $26 | Maintains | Equal-Weight |
What is the target price for H&R Block (HRB)?
The latest price target for H&R Block (NYSE: HRB) was reported by Goldman Sachs on August 16, 2023. The analyst firm set a price target for $32.00 expecting HRB to fall to within 12 months (a possible -9.48% downside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for H&R Block (HRB)?
The latest analyst rating for H&R Block (NYSE: HRB) was provided by Goldman Sachs, and H&R Block maintained their sell rating.
When is the next analyst rating going to be posted or updated for H&R Block (HRB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of H&R Block, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for H&R Block was filed on August 16, 2023 so you should expect the next rating to be made available sometime around August 16, 2024.
Is the Analyst Rating H&R Block (HRB) correct?
While ratings are subjective and will change, the latest H&R Block (HRB) rating was a maintained with a price target of $28.00 to $32.00. The current price H&R Block (HRB) is trading at is $35.35, which is out of the analyst's predicted range.